VTYX — Ventyx Biosciences Inc

Ventyx Biosciences Inc (VTYX) is a biotechnology company listed on NASDAQ. It is led by Sheila K. Gujrathi M.D., based in 12790 El Camino Real, San Diego, CA, United States, 92130, with about 83 employees. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.

Net income was -$77.3M. VTYX currently screens at market cap $1.00B.

Use this VTYX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VTYX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VTYX SEC filings page. Lician reads the product cache first so this HTML stays unique to Ventyx Biosciences Inc even when a live quote feed is slow.